Travere Therapeutics, Inc. ( (TVTX) ) has released its Q3 earnings. Here is a breakdown of the information Travere Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering therapies for rare diseases, with a notable emphasis on nephroprotective treatments.
In its third-quarter 2025 financial report, Travere Therapeutics highlighted significant growth in its product sales, particularly for FILSPARI (sparsentan), and announced strategic milestones that bolster its financial standing.
The company reported a remarkable 155% year-over-year increase in U.S. net product sales of FILSPARI, reaching $90.9 million, contributing to a total revenue of $164.9 million for the quarter. Additionally, Travere achieved a $40 million market access milestone in the EU and retired $69 million of convertible notes, strengthening its financial foundation.
Travere’s research and development expenses remained stable, while selling, general, and administrative expenses increased due to preparations for a potential FSGS launch. The company achieved a net income of $25.7 million, a significant turnaround from a net loss in the previous year, reflecting strong commercial execution and confidence in FILSPARI.
Looking ahead, Travere is well-positioned for potential FDA approval of FILSPARI for FSGS in early 2026 and continues to make progress in its clinical trials and strategic partnerships, aiming to expand its impact on the rare disease community.